Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 16;39(3):229–241. doi: 10.14348/molcells.2016.2244

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Korean Society for Molecular and Cellular Biology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Fig. 7. — miR-326 inhibitor enhances sensitivity to EGFR inhibitors. (A) Malme3M^R cells were transfected with the indicated inhibitor (each at 10 nM) along with the indicated siRNA (each at 10 nM). At 48 h after transfection, cell lysates were subjected to Western blot analysis. (B) Malme3M^R cells were transfected with the indicated inhibitor (each at 10 nM) along with the indicated siRNA (each at 10 nM). At 24 h after transfection, cells were treated with various concentrations of gefitinib for 24 h, followed by MTT assays. (C) Malme3M^R cells were transfected with the indicated inhibitor (each at 10 nM) along with the indicated siRNA (each at 10 nM). At 24 h after transfection, cells were then treated with gefitinib (10 μM) for 24 h, followed by caspase-3 activity assays. ^**p < 0.005. (D) Malme3M^R cells were transfected with the indicated inhibitor (each at 10 nM) along with the indicated siRNA (each at 10 nM). At 24 h after transfection, cells were then treated with gefitinib (10 μM) for 24 h, followed by Western blot analysis. (E) Malme3M cells were treated with EGF (50 ng/ml) for various time intervals. Cell lysates prepared at each time point were subjected to Western blot analysis and qRT-PCR analysis. Malme3M cells were pretreated with gefitinib (10 μM). The next day, cell were then treated with EGF (50 ng/ml) for 2 h, followed by qRT-PCR analysis (right panel). ^*p < 0.05; ^**p < 0.005.